We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.54%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.45B
AUM Growth
-$54.5M
Cap. Flow
+$154M
Cap. Flow %
10.62%
Top 10 Hldgs %
43.38%
Holding
129
New
42
Increased
32
Reduced
24
Closed
24

Top Buys

Rank Stock Value
1
LH icon
Labcorp
LH
+$37.6M
2
CYH icon
Community Health Systems
CYH
+$28.3M
3
ASND icon
Ascendis Pharma A/S
ASND
+$27.8M
4
CTLT
CATALENT, INC.
CTLT
+$23M
5
MASI
Masimo
MASI
+$18.2M

Top Sells

Rank Stock Value
1
QGEN icon
Qiagen
QGEN
+$26.7M
2
AMRN
Amarin Corp
AMRN
+$24.9M
3
OGN icon
Organon & Co
OGN
+$21.2M
4
DHR icon
Danaher
DHR
+$17.4M
5
AMN icon
AMN Healthcare
AMN
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 80.74%
2 Miscellaneous 17.65%
3 Industrials 1.16%
4 Financials 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOCO
51
DELISTED
GoHealth
GOCO
$6.35M 0.44%
84,115
+79,522
+1,731% +$8.42M
HRC
52
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$4.5M 0.31%
+30,000
New +$4.05M
HRC
53
CALL
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$4.41M 0.31%
+29,400
New +$3.97M
LXRX icon
54
Lexicon Pharmaceuticals
LXRX
$1.02B
$4.2M 0.29%
872,694
+643,405
+281% +$2.64M
APLS
55
CALL
DELISTED
Apellis Pharmaceuticals
APLS
$4.17M 0.29%
+126,400
New +$7.1M
ARKK icon
56
ARK Innovation ETF
ARKK
$6.46B
$3.87M 0.27%
35,000
-50,000
-59% -$6.02M
SRGA
57
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$3.82M 0.26%
116,951
-12,452
-10% -$456K
EDIT icon
58
CALL
Editas Medicine
EDIT
$485M
$3.7M 0.26%
+90,000
New +$4.93M
MRK icon
59
CALL
Merck
MRK
$366B
$3.66M 0.25%
48,700
– –
DXCM icon
60
DexCom
DXCM
$34.3B
$3.5M 0.24%
25,604
-12,496
-33% -$1.58M
SIBN icon
61
SI-BONE Inc
SIBN
$861M
$3.21M 0.22%
+150,000
New +$3.8M
ISRG icon
62
Intuitive Surgical
ISRG
$132B
$3.13M 0.22%
9,435
+1,686
+22% +$566K
EVH icon
63
Evolent Health
EVH
$520M
$3.11M 0.21%
+100,170
New +$2.4M
KRTX
64
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$3.06M 0.21%
+25,000
New +$2.89M
A icon
65
Agilent Technologies
A
$43.4B
$2.94M 0.2%
18,660
+3,399
+22% +$550K
PBYI icon
66
Puma Biotechnology
PBYI
$468M
$2.79M 0.19%
+397,940
New +$2.98M
VRDN icon
67
Viridian Therapeutics
VRDN
$2.61B
$2.63M 0.18%
+160,000
New +$2.35M
AUTL
68
Autolus Therapeutics
AUTL
$623M
$2.61M 0.18%
398,074
-75,000
-16% -$474K
LQDA icon
69
Liquidia Corp
LQDA
$6.06B
$2.56M 0.18%
929,049
-50,000
-5% -$130K
MORF
70
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.47M 0.17%
+43,600
New +$2.64M
OM icon
71
Outset Medical
OM
$74.1M
$2.35M 0.16%
3,167
-3,986
-56% -$2.72M
ADAP
72
DELISTED
Adaptimmune Therapeutics
ADAP
$2.3M 0.16%
+444,887
New +$2M
HSTM icon
73
HealthStream
HSTM
$859M
$2.22M 0.15%
77,812
– –
MREO
74
Mereo BioPharma
MREO
$40.3M
$2.18M 0.15%
+899,569
New +$2.38M
ANAB icon
75
AnaptysBio
ANAB
$1.67B
$2.12M 0.15%
+78,054
New +$1.98M
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2021 Portfolio in Review

As of Q3 2021, Eversept Partners held 129 positions worth $1.45B, down 3.6% from $1.5B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Eversept Partners deployed $154M of net new capital in Q3 2021, opening 42 new positions and adding to 32 existing holdings. Its largest new stake was Labcorp: 149,354 shares worth $36.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 65% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Qiagen, an estimated $26.7M trimmed.

  • Eversept Partners's largest Q3 2021 buy was Labcorp: 149,354 shares worth $36.1M.
  • Eversept Partners added most to Community Health Systems in Q3 2021, an estimated $28.3M increase.
  • Eversept Partners's biggest Q3 2021 reduction was Qiagen, cutting an estimated $26.7M.
  • Eversept Partners fully exited Organon & Co in Q3 2021, selling an estimated $21.2M.
  • Eversept Partners's ten largest holdings make up 43% of its $1.45B portfolio in Q3 2021.
  • Eversept Partners opened 42 new positions and closed 24 in Q3 2021.
  • Eversept Partners's portfolio value fell 3.6% quarter-over-quarter to $1.45B.

Based on Eversept Partners's 13F filing for Q3 2021, filed 15 Nov 2021.